Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m
Published In/Presented At
Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, B., Gaballa, S., Khimani, F., Elmariah, H., Nishihori, T., Lazaryan, A., Freeman, C., Davila, M. L., … Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and cellular therapy, 28(12), 829.e1–829.e8. https://doi.org/10.1016/j.jtct.2022.09.009
Medical Education | Medicine and Health Sciences
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students